Drug Type Gene editing |
Synonyms |
Target |
Mechanism STMN2 modulators(stathmin 2 modulators) |
Active Indication |
Inactive Indication- |
Originator Organization Arbor Biotechnologies, Inc.Startup |
Active Organization Arbor Biotechnologies, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Preclinical | US | Arbor Biotechnologies, Inc.Startup | 01 Dec 2024 |